· COMPANY
  · INVESTOR RELATIONS
  · FACES PRODUCTS
  · SUCCESS STORIES
  · TECH SUPPORT
  · Media Center
    · Main Page
    · Press Releases

    · Image Bank
    · Videos
    · Media Contacts
  · TRAINING
  · RESELLERS
  · ORDER PRODUCTS


1-800-516-4065

IQ Biometrix, Inc

PO Box 270323
Houston, TX 77277-0323



 


PRESS RELEASES



IQ Biometrix Announces DOD Defense Research Technologies Grant

FREMONT, Calif., Oct. 21, 2003
IQ Biometrix Inc. a worldwide provider of integrated law enforcement and security solutions and Defense Research Technologies, Inc. announced today a $300,000 Department of Defense grant. The grant is for the development of a prototype microfluidic metabolic rate monitor for the US Army Medical Research and Materiel Command. The monitor will be easy to use, high performance, continuous, low-cost, lightweight, and low-power. It will potentially have extensive applications in biomedical clinical settings, portable field environments such as the battlefield, security and safety applications, and biological and chemical counter-terrorism.
IQ Biometrix scientist Michael Polcha will lead IQBM's efforts in developing and testing this new technology. Tadeusz M. Drzewiecki, Dr. Eng., an expert in micro-fluidic technologies, is the principal investigator on the grant. Joseph M. Iseman, Ph.D. brings experience in both microfluidic systems and biometrics, and Jerry Calkins, Ph.D., M.D. is a Professor of Clinical Anesthesiology at the University of Arizona College of Medicine.

"This grant and collaboration with the Department of Defense and DRT cascades well with IQ Biometrix's long-term business strategy to become a solutions provider. The technology will expand our existing intellectual property into new areas of bioanalysis and bioterrorism," said William Scigliano, CEO and President of IQ Biometrix. "IQBM's scientists are looking forward to working with DRT on the Metabolic Rate Monitor and evaluating other technologies of mutual interest for future collaboration and commercial applications."

Defense Research Technologies, Inc., based in Rockville, Maryland, has been in the lead of fluidic sensors and control systems development for over eighteen years. DRT is the recipient of numerous government grants and contracts from the Department of Defense, National Institutes of Health, and Department of Energy, and has a proven track record of spinning-off technology developed with government funding.

About IQ Biometrix, Inc.

IQ Biometrix, Inc. (IQBM) provides law enforcement and security technology solutions for government and private industry. IQ Biometrix, an innovative California-based company is a leading provider of facial composite technology for law enforcement agencies in North America. FACES is currently used by thousands of policing agencies worldwide, including the Central Intelligence Agency and the Federal Bureau of Investigation. IQBM is currently developing new applications based on this foundation technology tailored to meet the needs of national, business and personal security. Its solutions practice is focused on integrating IQBM and partner technologies to provide customized responses to client needs. Further information about IQBM can be found at www.iqbiometrix.com.

Safe Harbor Statement

To the extent that any of the statements contained herein are forward-looking, such statements are based on current expectations that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, growth in the NAS market, market acceptance of products, the development of new products, the enhancement of existing products, manufacturing delays, dependence on principal customers, competitive pricing pressures, product volume and mix, global economic conditions, dependence on international operations, availability of key components, timing of orders received, and introduction of competitor products having technological and/or pricing advantages. As a result, the Company's operating results may fluctuate, especially when measured on a quarterly basis. Actual results may differ materially from such expectations. Investors are directed to consider other risks and uncertainties in documents, including forms 8K and 10QSB, filed by the com! pany with the Securities and Exchange Commission, www.sec.gov.


Contact:
IQ Biometrix, Inc.
Equity Communications
Robert Schechter, 212-499-6809
rschechter@iqbiometrix.com


Back to Press Releases







Copyright © 2003 IQ Biometrix - All rights reserved.

TOP